ERS Genomics licenses gene editing tech to FASMAC

By The Science Advisory Board staff writers

ERS Genomics, which has access to foundational CRISPR/Cas9 intellectual property co-owned by Emmanuelle Charpentier, has signed an agreement with FASMAC of Japan.

Under the terms of the nonexclusive agreement, FASMAC acquires the rights to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it.

FASMAC was established in 2001 to provide food analysis and biotechnology products and services, including DNA and RNA synthesis products, DNA sequencing services, food testing services, and genetic analysis reagents and kits.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?